*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
The peptide used to generate this antibody is available for purchase (GTX88654-PEP).
TBS pH7.3, 0.5% BSA
0.02% Sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Peptide with sequence C-TDLHLRYQKDKK, from the internal region of the protein sequence according to NP_000375.2.
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
apolipoprotein B , FLDB , LDLCQ4 , apoB-100 , apoB-48
Cytoplasm , Secreted
This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]